natgillin/translations-raw huggingface dataset:
At least two weeks before starting Soliris treatment, patients must be vaccinated against meningitis caused by the bacterium Neisseria meningitidis and revaccinated according to current guidelines.
Najmanje dva tjedna prije početka liječenja lijekom Soliris bolesnici se moraju cijepiti protiv meningitisa koji uzrokuje bakterija Neisseria meningitidis te se moraju ponovno cijepiti u skladu s aktualnim smjernicama.
At licensed posology, Rebif 22 micrograms has been demonstrated to decrease the incidence (approximately 30% over 2 years) and severity of clinical relapses in patients with at least 2 exacerbations in the previous 2 years and with an EDSS of 0-5.0 at entry.
Uz odobreno doziranje, za Rebif 22 mikrograma dokazano je smanjenje incidencije (približno 30% nakon 2 godine) i težine kliničkih relapsa kod bolesnika s najmanje 2 egzacebracije u prethodne 2 godine i EDSS vrijednosti od 0-5,0 na početku kliničkog ispitivanja.
At licensed posology, Rebif 44 micrograms has been demonstrated to decrease the incidence (approximately 30% over 2 years) and severity of clinical relapses in patients with at least 2 exacerbations in the previous 2 years and with an EDSS of 0-5.0 at entry.
Uz odobreno doziranje, za Rebif 44 mikrograma dokazano je smanjenje incidencije (približno 30% nakon 2 godine) i težine kliničkih relapsa kod bolesnika s najmanje 2 egzacebracije u prethodne 2 godine i EDSS vrijednosti od 0-5,0 na početku kliničkog ispitivanja.
At low oxygen saturation, nitric oxide can combine with deoxyhaemoglobin to transiently form nitrosylhaemoglobin, which is converted to nitrogen oxides and methaemoglobin upon exposure to oxygen.
Pri niskoj zasićenosti kisikom dušikov (II)oksid se veže s deoksihemoglobinom i prijelazno stvara nitrozilhemoglobin, koji se nakon izlaganja kisiku pretvara u dušikove okside i methemoglobin.
At lower doses (10 mg/m2–20 mg/m2) Caelyx displayed linear pharmacokinetics.
Farmakokinetika Caelyxa u manjim dozama (10 mg/m2 – 20 mg/m2) je linearna.
At maternally toxic doses in rats, ivacaftor produced reductions in foetal body weight and an increase in the incidence of cervical ribs, hypoplastic ribs, wavy ribs and sternal irregularities, including fusions.
U dozama koje su bile toksične za skotne ženke štakora, ivakaftor je prouzročio smanjenje tjelesne težine fetusa i povećanje incidencije cervikalnih rebara, hipoplastičnih rebara, valovitih rebara i nepravilnosti prsne kosti, uključujući spajanja.
At maximum recommended doses, there is an 80-fold selectivity over PDE1, and over 700-fold over PDE2, 3, 4, 7, 8, 9, 10 and 11.
Kod maksimalnih preporučenih doza prisutna je 80 puta veća selektivnost u usporedbi s PDE1 te preko 700 puta u usporedbi s PDE2, 3, 4, 7, 8, 9, 10 i 11.
At maximum recommended doses, there is an 80-fold selectivity over PDE1, and over 700-fold over PDE2, 3, 4, 7, 8, 9, 10 and 11.
Kod maksimalnih preporučenih doza, prisutna je 80 puta veća selektivnost u usporedbi s PDE1 te preko 700 puta u usporedbi s PDE2, 3, 4, 7, 8, 9, 10 i 11.
At mg/kg/day (approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed.
Pri dozi od 5 mg/kg/dan (otprilike odgovara AUC izloženosti u ljudi pri dozi od 100 mg), zapaženi su samo mjehurići.
At Month 1, 4, and 6 post-transplant, the mean (range) trough concentrations of belatacept were 22.7 (11.1-45.2),
U 1., 4. odnosno 6. mjesecu nakon presađivanja, prosječne (raspon) najniže koncentracije belatacepta bile su 22,7 (11,1-45,2), 7,6 (2,1-18,0) odnosno
At Month 24, 48.3% (95% CI: 39.4, 57.3, N=116) of subjects who completed the recommended primary immunization still had PRNT50 titers of ≥1:10.
PRNT50 ≥ 1:10 bila 48,3 % (95 % CI: 39,4, 57,3, N = 116) u ispitanika koji su završili preporučenu primarnu imunizaciju.
At Month 24, the reduction from baseline values in percentage of predicted FEV1 was 2.7% for fingolimod 0.5 mg and 1.2% for placebo, a difference that resolved after treatment discontinuation.
U 24. mjesecu, smanjenje od početnih vrijednosti u postotku predviđenog FEV1 iznosilo je 2,7% za fingolimod 0,5 mg te 1,2% za placebo, a nakon prekida liječenja više nije bilo te razlike.
At month 3, Geometric Mean Titres (GMT) were 223.0 mIU/ml and 50.1 mIU/ml in the Fendrix and control groups respectively, with 41.0% and 15.9% of subjects with anti-HBs antibody titres 100 mIU/ml respectively.
U 3. mjesecu, geometrijska srednja vrijednost titra (GMT) bila je 223,0 mIU/ml u skupini koja je primila Fendrix i 50,1 mIU/ml u kontrolnoj skupini, s 41,0% odnosno 15,9% ispitanika s titrom anti- HBs antitijela  100 mIU/ml.
At month 36, 80.4% of these patients retained protective antibody levels (anti-HBs titres  10mIU/ml), as compared to 51.3% of patients who received a commercially available hepatitis B vaccine.
U 36. mjesecu, 80,4% od tih bolesnika zadržalo je zaštitne razine antitijela (anti-HBs titar  10 mIU/ml), u usporedbi s 51,3% bolesnika koji su primili komercijalno dostupno cjepivo protiv hepatitisa B.
At month 7, GMTs were 3559.2 mIU/ml and 933.0 mIU/ml in the Fendrix and control groups who received the commercially available hepatitis B vaccine respectively, with 83.1% and 67.5% of subjects with anti-HBs antibody titres 100 mIU/ml respectively.
U 7. mjesecu, geometrijska srednja vrijednost titra (GMT) bila je 3559,2 mIU/ml u skupini koja je primila Fendrix i 933,0 mIU/ml u kontrolnoj skupini, s 83,1% odnosno 67,5% ispitanika s titrom anti- HBs antitijela  100 mIU/ml.
At Month 7, in the Per Protocol population, the immune response in girls aged 9-13 years (n=241) who received 2 doses of Gardasil (at 0, 6 months) was non–inferior and numerically higher to the immune response in women aged 16-26 years (n=246) who received 3 doses of Gardasil (at 0, 2, 6 months).
U 7. mjesecu ispitivanja, u populaciji prema protokolu, imunološki odgovor u djevojčica u dobi od 9 do 13 godina (n=241) koje su primile 2 doze cjepiva Gardasil (prema rasporedu 0 i 6 mjeseci) bio je neinferioran i brojčano viši od imunološkog odgovora žena u dobi od 16 do 26 godina (n=246) koje su primile 3 doze cjepiva Gardasil (prema rasporedu 0, 2, 6 mjeseci).
At monthly intervals during complete course of the treatment
U mjesečnim intervalima tijekom cijelog liječenja
At one year (primary analysis), 91.3 % (p=0.005) of patients receiving Bonviva 150 mg once monthly had a lumbar spine BMD increase above or equal to baseline (BMD responders), compared with
Nakon jedne godine (primarna analiza) u 91,3% (p=0,005) bolesnika koji su primali lijek Bonviva 150 mg jedanput mjesečno došlo je do povećanja BMD lumbalne kralježnice više ili jednako početnoj vrijednosti (BMD responderi) u usporedbi s 84% bolesnika koji su primali ibandronatnu kiselinu
At one year post vaccination in these same subjects, compared with ACWY-PS, a higher proportion of subjects vaccinated with Menveo had hSBA ≥1:8 for serogroups C, W135, and Y, with comparable levels for serogroup A. Similar findings were observed in the comparison of hSBA GMTs.
Godinu dana nakon cijepljenja u istih ispitanika, u usporedbi s ACWY-PS, veći udio ispitanika koji su primili cjepivo Menveo je imao hSBA ≥1:8 za serogrupe C, W135 i Y, s usporedivim razinama za serogrupu A. Slični rezultati dobiveni su kod usporedbe hSBA GMTs.
At one year, the average weight loss (using LOCF methodology) among these Week 16 Responders who received naltrexone / bupropion was 11.3%, with 55% losing ≥10% bodyweight.
Prve godine, prosječni gubitak težine (koristeći LOCF metodologiju) među onima koji su odgovorili na liječenje u 16. tjednu i koji su primali naltrekson / bupropion bilo je 11,3 %, od kojih je 55 % izgubilo ≥ 10 % tjelesne težine.
At Other Endpoints
Ostali ishodi
At peak plasma concentration, the mean plasma to blood drug concentration ratio was ~ 1.0 and the mean semen to plasma drug concentration ratio was
Pri vršnoj koncentraciji u plazmi omjer srednje vrijednosti lijeka u plazmi i koncentracije lijeka u krvi iznosio je ~ 1,0, a omjer srednje vrijednosti koncentracije lijeka u spermi i koncentracije lijeka u plazmi iznosio je ~ 4,0.
At pH 4, insulin glargine is completely soluble.
Inzulin glargin potpuno je topljiv pri pH 4.
At poorly tolerated doses in rats and dogs (> 10 or 7 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and> 4 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC), decreased reticulocyte counts and regenerative bone marrow erythroid hyperplasia (rats only) were observed in short term studies.
U slabo podnošljivim dozama u štakora i pasa (> 10 ili 7 puta kliničke izloženosti odraslih ili pedijatrijskih bolesnika s ITP-om pri dozi od 75 mg/dan i > 4 puta kliničke izloženosti bolesnika s HCV-om pri dozi od 100 mg/dan, mjereno AUC-om) zabilježeni su smanjen broj retikulocita i regenerativna eritroidna hiperplazija koštane srži (samo u štakora) tijekom kratkoročnih studija.
At present the effect of raltegravir on darunavir plasma concentrations does not appear to be clinically relevant.
Za sada se čini učinak raltegravira na koncentracije darunavira u plazmi nije klinički značajan.
At present, there is insufficient evidence to guide clinical decision making in patients with resolved intracranial hypertension.
Za sada nema dovoljno dokaza na temelju kojih bi se mogle donositi kliničke odluke za bolesnike s prethodnom intrakranijalnom hipertenzijom.
At present, there is insufficient evidence to guide clinical decision-making in patients with resolved intracranial hypertension.
Za sada nema dovoljno dokaza na temelju kojih bi se mogle donositi kliničke odluke za bolesnike s prethodnom intrakranijalnom hipertenzijom.
At present, there is insufficient evidence to guide clinical decision-making in patients with resolved intracranial hypertension.
Za sada nema dovoljno dokaza na temelju kojih bi se mogle donositi kliničke odluke za bolesnike s prethodnom riješenom intrakranijalnom hipertenzijom.
At present, there is only limited information on the use of Invirase/ritonavir in children and in adults over the age of 60 years.
Trenutno su dostupni tek ograničeni podaci o primjeni lijekova Invirase/ritonavir u djece te odraslih starijih od 60 godina.
At request of the European Medicines Agency;
Na zahtjev Europske agencije za lijekove;
At retigabine doses of up to 750 mg/day, there was no clinically significant effect of retigabine on the pharmacokinetics of the estrogen (ethinyl estradiol) or progestogen (norethindrone) components of the oral contraceptive pill.
Pri dozama retigabina do 750 mg dnevno nije bilo klinički značajnog učinka retigabina na farmakokinetiku estrogenske (etinilestradiol) ili progesteronske (noretindron) komponente oralnih kontraceptiva.
At retreatment a dose reduction may be considered according to the dose reduction schedule (see Table 1).
Pri ponovnom uvođenju lijeka možda će trebati razmotriti smanjenje doze u skladu s rasporedom smanjivanja doze (vidjeti Tablicu 1).
At Risk 12
Pojedinačni centar 12
At steady state meals with low fat content reduce Cmax by 76% and AUC0- tau by 67% in hypertensive patients.
U stanju dinamičke ravnoteže obroci s niskim sadržajem masti smanjuju Cmax za 76% i AUC0-tau za 67% u hipertenzivnih bolesnika.
At steady state plasma concentrations of N-desmethyl metabolite are approximately 16 % versus 61 % those of sildenafil after IV and oral dosing, respectively.
U stanju dinamičke ravnoteže koncentracije N-dezmetil metabolita nakon intravenske primjene iznose približno 16% koncentracije sildenafila, dok nakon peroralne primjene one iznose 61% koncentracije sildenafila.
At steady state, lopinavir is approximately 98 − 99% bound to serum proteins.
U stanju dinamičke ravnoteže, oko 98 – 99% lopinavira vezano je na serumske proteine.
At steady state, lopinavir protein binding remains constant over the range of observed concentrations after 400/100 mg Kaletra twice daily, and is similar between healthy volunteers and HIV-positive patients.
U stanju dinamičke ravnoteže, vezanje lopinavira ostaje konstantno u rasponu koncentracija koje se postižu pri uzimanju lijeka Kaletra u dozi od 400/100 mg dvaput na dan, i istovjetno je između zdravih dragovoljaca i bolesnika s HIV-om.
At steady state, mean peak concentrations of 1.7µg/mL to 15.6µg/mL were reported for total daily doses of 200mg to 1200mg.
U stanju dinamičke ravnoteže, srednje vršne koncentracije od 1,7 µg/ml do 15,6 µg/ml prijavljene su za ukupne dnevne doze od 200 mg do 1200 mg.
At steady state, opicapone 50 mg significantly increased the extent of levodopa systemic exposure approximately 2 fold compared to placebo following a single oral administration of either 100/25 mg levodopa/carbidopa or 100/25 mg levodopa/benserazide administered 12 h after the opicapone dose.
U stanju dinamičke ravnoteže, 50 mg opikapona značajno je povećalo opseg sistemske izloženosti levodopi, otprilike za 2 puta u usporedbi s placebom nakon jednokratne peroralne primjene 100/25 mg levodope/karbidope ili 100/25 mg levodope/benzerazida primijenjenih 12 sati nakon doze opikapona.
At steady state, peak-to-trough fluctuations in darifenacin concentrations are small (PTF: 0.87 for 7.5 mg and 0.76 for 15 mg), thereby maintaining therapeutic plasma levels over the dosing interval.
U stanju dinamičke ravnoteže kolebanja između vršne i najniže koncentracije (PTF – peak-to-trough fluctuations) su mala (PTF: 0,87 za 7,5 mg i 0,76 za 15 mg), zbog čega se terapijske razine u plazmi održavaju tijekom intervala doziranja.
At steady state, the concentration of miglustat in cerebrospinal fluid of six type 3 Gaucher disease patients was 31.4–67.2% of that in plasma.
U stanju dinamičke ravnoteže, koncentracija miglustata u cerebrospinalnom likvoru kod bolesnika s 6 Gaucherovom bolesti tipa 3 bila je 31,4–67,2% koncentracije u plazmi.
At steady state, the mean Cmax values for enzalutamide and its active metabolite are 16.6 μg/mL (23% coefficient of variation [CV]) and 12.7 μg/mL (30 %CV), respectively.
U stanju dinamičke ravnoteže, srednja vrijednost Cmax enzalutamida je 16,6 μg/ml (23% koeficijent varijacije [CV]), a njegovog djelatnog metabolita 12,7 μg/ml (30% CV).
At steady state, the systemic exposures in paediatric patients weighing 10–20 kg, 20–40 kg and > 40 kg were 43%, 67% and 75%, respectively, of the adult systemic exposure.
U stanju dinamičke ravnoteže, sistemske izloženosti pedijatrijskih bolesnika koji su težili 10–20 kg, 20-40 kg i > 40 kg iznosile su 43%, 67%, odnosno 75% sistemske izloženosti kod odraslih.
At steady-state AUC is approximately 1.5 fold increased compared to the single dose.
AUC u stanju dinamičke ravnoteže je 1,5 puta veći nego nakon primjene jedne doze lijeka.
At steady-state, AUC was 6,165 ng·h/mL (CV: 133%, n = 7), which is similar to the exposure observed in adult PAH patients receiving 125 mg twice daily and taking into account a blood/plasma distribution ratio of 0.6.
U stanju dinamičke ravnoteže AUCτ je bila 6165 ng•h/mL (CV: 133%, n = 7), što je slično izloženosti zabilježenoj u odraslih bolesnika s PAH-om koji su primali 125 mg dvaput dnevno i uzimajući u obzir omjer distribucije u krvi i plazmi od 0,6.
At steady-state, brinzolamide and its metabolite RBC concentrations ranged from 22.0 to 46.1 and 17.1 to 88.6 µM, respectively.
U stanju dinamičke ravnoteže koncentracije brinzolamida i njegovog metabolita u eritrocitima bile su od 22,0 do 46,1 M, odnosno 17,1 do 88,6
At steady-state, circulating plasma concentrations are typically maintained within a 2- to 3-fold range over the 24-hour dosing interval.
U stanju dinamičke ravnoteže, koncentracije koje cirkuliraju u plazmi su tijekom 24-satnog intervala doziranja u pravilu održane unutar raspona od dvostruke do trostruke razine normalnih vrijednosti.
At steady-state, tadalafil (40 mg once per day) increased ethinylestradiol exposure (AUC) by 26 % and Cmax by 70 % relative to oral contraceptive administered with placebo.
U stanju dinamičke ravnoteže tadalafil (40 mg jedanput na dan) je povećao izloženost etinilestradiolu (AUC) za 26%, a Cmax za 70% u odnosu na primjenu oralnog kontraceptiva s placebom.
At steady-state, the exposure ratio for the two diastereomers is approximately 2:1, with the predominant diastereomer being pharmacologically active.
U stanju dinamičke ravnoteže, omjer izloženosti za dva dijastereoizomera iznosi oko 2:1, s tim da je farmakološki aktivan onaj dijastereoizomer koji prevladava.
At study completion/ terminationb (N=23)
Pri završetku / prekidu ispitivanjab (N=23)
At study entry, 41% of randomized patients had PSA progression only, whereas 59% of patients had radiographic progression.
Pri uključenju u ispitivanje, 41% randomiziranih bolesnika imalo je progresiju bolesti samo po PSA, dok je 59% bolesnika imalo radiološke znakove progresije bolesti.
At study entry, patients must have had penile curvature deformity of at least 30 degrees in the stable phase of Peyronie’s disease.
Na ulasku u ispitivanje, bolesnici su morali imati deformirajuću zakrivljenost penisa od najmanje 30 stupnjeva u stabilnoj fazi Peyronijeve bolesti.
At study entry, patients were treated with PAH medications (most frequently PDE-5 inhibitor [sildenafil] alone [35.9%], bosentan alone [10.9%], and a combination of bosentan, iloprost, and sildenafil in 10.9% of patients) and continued their PAH treatment during the study.
Pri ulasku u studiju, bolesnici su bili liječeni lijekovima za PAH (najčešće inhibitorom PDE- 5 [sildenafil] u monoterapiji [35,9%], bosentanom u monoterapiji [10,9%] i kombinacijom bosentana, iloprosta i sildenafila u 10,9% bolesnika) i nastavili su svoje liječenje za PAH tijekom studije.
At study entry, patients were treated with PAH-medications (most frequently PDE-5 inhibitor [sildenafil] alone [35.9%], bosentan alone [10.9%], and a combination of bosentan, iloprost, and sildenafil in 10.9% of patients) and continued their PAH treatment during the study.
Pri ulasku u studiju, bolesnici su bili liječeni lijekovima za PAH (najčešće inhibitorom PDE- 5 [sildenafil] u monoterapiji [35,9%], bosentanom u monoterapiji [10,9%] i kombinacijom bosentana, iloprosta i sildenafila u 10,9% bolesnika) i nastavili su svoje liječenje za PAH tijekom studije.
At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.
Na početku ispitivanja bolesnicima su dane niže doze kombiniranih lijekova koje su titrirane do pune doze liječenja do 2. tjedna.
At study start, less than half of the patients included (45.3% = 29/64) had bosentan treatment alone not combined with other PAH-medication.
Na početku studije manje od polovice uključenih bolesnika (45,3% = 29/64) liječeno je bosentanom u monoterapiji, bez kombinacije s drugim lijekovima za PAH.
At such doses, the symptoms are not usually life-threatening and generally resolve within 24 hours if symptomatic treatment is given.
Uz takve doze simptomi obično nisu opasni po život i najčešće nestaju unutar 24 sata ako se primijeni simptomatsko liječenje.
At supra-therapeutic doses (75 mg and 300 mg once daily), rilpivirine has been associated with prolongation of the QTc interval of the electrocardiogram (ECG) (see sections 4.5, 4.8, and 5.2).
Rilpivirin u dozama iznad terapijskih (75 mg i 300 mg jedanput na dan) povezan je s produljenjem QTc intervala na elektrokardiogramu (EKG) (vidjeti dijelove 4.5, 4.8 i 5.2).
At supratherapeutic doses (75 mg once daily and 300 mg once daily), rilpivirine has been associated with prolongation of the QTc interval of the electrocardiogram (ECG) (see sections 4.5, and 4.9).
Pri supraterapijskim dozama (75 mg jedanput na dan i 300 mg jedanput na dan), rilpivirin je povezan s prolongacijom QTc intervala na elektrokardiogramu (EKG) (vidjeti dijelove 4.5 i 4.9).
At ten and fourteen days after administration, urine concentrations were 1.3 g/ml and 0.7 g/ml, respectively.
Deseti i četrnaesti dan nakon primjene koncentracije u urinu bile su 1,3 g/ml, odnosno 0,7 g/ml.
At that dose-level, in 12 volunteers given Carbaglu tablets, plasma concentration peaked at 2.6 µg/ml (median; range 1.8-4.8) after 3 hours (median; range 2-4).
Pri tim dozama, kod 12 dobrovoljaca koji su dobivali Carbaglu tablete, vršna plazmatska koncentracija bila je 2,6 μg/ml (medijan; raspon 1,8-4,8) nakon 3 sata (medijan; raspon 2- 4).
At that point check that you have the correct dose.
U tom trenutku provjerite jeste li podesili ispravnu dozu.
At that time the remaining activity represents about 1/1000 of the initial activity in the body.
Nakon tog vremena preostala radioaktivnost u tijelu predstavlja 1/1000 početne aktivnosti.
At the + 2 h time point (the time corresponding to the morning efficacy peak) for the primary efficacy visit at Month 3, the percentage of patients with an IOP less than 18 mmHg was 61.7% in the SIMBRINZA group, 40.1% in the Brinzolamide group, and 40.0% in the Brimonidine group.
U vremenskoj točki +2 h (vrijeme koje odgovara vršnoj jutarnjoj učinkovitosti) pri primarnoj kontroli učinkovitosti u 3. mjesecu, postotak bolesnika s IOT-om nižim od 18 mm Hg iznosio je 61,7% u skupini liječenoj SIMBRINZOM, 40,1% u skupini liječenoj brinzolamidom i 40,0% u onoj liječenoj brimonidinom.
At the + 2 h time point (the time corresponding to the morning efficacy peak) for the primary efficacy visit at Month 3, the percentage of patients with an IOP less than 18 mmHg was 65.6% in the SIMBRINZA group and 63.7% in the Brinzolamide + Brimonidine groups.
U vremenskoj točki +2 h (vrijeme koje odgovara vršnoj jutarnjoj učinkovitosti) pri primarnoj kontroli učinkovitosti u 3. mjesecu, postotak bolesnika s IOT-om nižim od 18 mm Hg iznosio je 65,6% u skupini liječenoj SIMBRINZOM i 63,7% u onoj liječenoj brinzolamidom + brimonidinom.
At the 100 micromol/kg dose, the mean distribution half life in normal subjects calculated by the method of residuals in 12 normal volunteers is 13.3 ± 6.8 min.
Pri dozi od 100 mikromola/kg srednje poluvrijeme distribucije u zdravih ispitanika, izračunato metodom određivanja ostatka u 12 zdravih dobrovoljaca, bilo je 13,3  6,8 min.
At the 12-week primary endpoint (24-hour trough FEV1), the 150 microgram dose resulted in a 130-180 ml increase compared to placebo (p<0.001) and a 60 ml increase compared to salmeterol 50 microgram twice a day (p<0.001).
Kao primarni ishod nakon 12 tjedana (24- satni najniži FEV1), doza od 150 mikrograma dovela je do povećanja od 130-180 ml u usporedbi s placebom (p<0,001) te povećanje od 60 ml u usporedbi sa salmeterolom u dozi od 50 mikrograma dva puta na dan (p<0,001).
At the 20 mg dose Levitra film-coated tablets, elderly (≥ 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (<65 years old).
Uz Levitra filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od < 65 godina).
At the 20 mg dose Vivanza film-coated tablets, elderly (≥ 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (<65 years old).
Uz Vivanza filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od < 65 godina).
At the 20 mg dose Vivanza film-coated tablets, elderly ( 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (<65 years old).
Uz Vivanza filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od < 65 godina).
At the 24-month follow-up, 19 (42.2%) converted to clinical AD.
U 19 (42,2%) bolesnika je nakon 24 mjeseci praćenja klinički dijgnosticirana Alzheimerova bolest.
At the 36-month follow-up, 81 (35%) converted to clinical AD.
Nakon 36-mjesečnog praćenja, u 81 (35%) bolesnika dijagnosticirana je klinička